INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

Volume 11, Number 8 • August 1990

Special Update

The Fifth Consensus Conference on Testing for Human Retroviruses

Sponsored by the Association of State and Territorial Public Health Laboratories

The Official Journal of The Society of Hospital Epidemiologists of America

https://doi.org/10.1017/S0899823X0008346X Published online by Cambridge University Press

https://doi.org/10.1017/S0899823X0008346X Published online by Cambridge University Press

Lowest Cost Per Dose[2]

Extensively Tested and Well Tolerated‡

State-of-the-art recombinant technology

14 million doses distributed in over 87 countries[3]

Switch to 'Engerix-B'

Can be used to complete a course of vaccination initiated with another hepatitis B vaccine[3,4]

Engerix-B®	Recombivax HB®†
20	10
Yes	Yes
Yes	No
Yes	Yes
Yes	No
Yes	No
Yes	No



Manufactured by
SmithKline Biologicals
Rixensart, Belgium

Distributed by
SmithKline Beecham Pharmaceuticals
Philadelphia, PA 19101

https://doi.org/10.1017/S0899823X0008346X Published online by Cambridge University Press

References:
1. Poovorawan Y, Sanpavat S, Pongpunlert W, et al: Protective efficacy of a recombinant DNA hepatitis B vaccine in neonates of HBe antigen-positive mothers. *JAMA* 1989; 261(22):3278–3281. 2. Based on Medi-Span* Hospital Formulary Pricing Guide, December 1989. 3. Data on file. SK&F. 4. Bush L, Moonsammy G, Boscia J: Evaluation of initiating a hepatitis B vaccination schedule with one vaccine and completing it with another *Hepatology* 1989;10:689.

https://doi.org/10.1017/S0899823X0008346X Published online by Cambridge University Press

VOLUME 11, NUMBER 8 AUGUST 1990

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

The ideas and opinions expressed by contributing authors do not necessarily reflect those of the editors or publisher.

Publisher: Infection Control and Hospital Epidemiology (ISSN-0899-623X) is published monthly by SLACK Incorporated. 6900 Grove Road Thorofare, New Jersey 08086 Telephone (609) 848-1000

Subscriptions: Requests should be addressed to the publisher (except Japan) In Japan contact Woodbell Incorporated. 4-22-11, Kitakasai, Edogawaku, Tokyo 134, Japan Subscription rates in the US and possessions Individual One year—$60 00. Two years-$95 00, Three years-5125 00. Institutional One year-570.00, Two years-5110 00, Three years-5150 00 Canada 518.00 additional each year all other countries 530 00 additional each year Single copies of current issues may be obtained for 58 00, United States and possessions; $16 Wall other countries

Change of address: Notice should be sent to the publisher six weeks in advance of effective date Include old and new addresses with zip codes The publisher cannot accept responsibility for undelivered copies Second-class postage is paid at Thorofare, New Jersey 08086. and additional entry pants Postmaster: Send address changes to SLACK Incorporated, 6900 Grove Road Thorofare, NJ 08086

As of Volume 1, Number 1, INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY is listed in *Index Medicus, Current Contents—Clinical Practice. Hospital Literature Index Cumulative Index to Nursing and Allied Health Literature,* and *Nursing Abstracts*

EDITORIAL OFFICES
Vanderbilt University School of Medicine
A-1131 Medical Center North
Nashville, TN 37232-2637
(615) 343-1095; (615) 343-1882 (FAX)
Email: iche@mcmail.vanderbilt.edu

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY®

SLACK Incorporated
6900 Grove Road
Thorofare, New Jersey 08086
(609) 848-1000

Vice President/Group Publisher
Richard N. Roash

Publisher
John C. Carter

Editorial Director
Jennifer Kilpatrick

Production Editor
Shirley P. Strunk, ELS

Assistant Editor
Eileen C. Anderer

Circulation Manager
Lester J. Robeson, CCCP

Production Director
Christine Malin

Production Coordinator
Joanne Patterson

Publishing Director/ Advertising
Wayne McCourt

Pharmaceutical Group Sales Director
Michael LoPresti

Advertising Sales Representative
Jennine Kane

Classified/Recruitment Sales Manager
Michele Burch

"Synergism..."

Synergism is the working relationship between two ingredients which results in performance superior to that achieved by each ingredient working separately.

Synergism is Sporicidin. Glutaraldehyde combined with an alkaline phenate system produces superior disinfecting properties.* Patented Sporicidin disinfects with substantually less glutaraldehyde than other products.

Synergism makes Sporicidin tuberculocidal in only ten minutes at room temprature, 68° F and above, when diluted 1:16. Other alkaline glutaraldehyde products cannot be diluted and/or require longer contact times with heating to 77°F.

Sporicidin fulfills the CDC definition of high level disinfection using the lowest concentration of glutaraldehyde... because of Synergism.

* *Journal of Clinical Microbiology, November 1985, p. 735 - 739*

Sporicidin
INTERNATIONAL

12000 Old Georgetown Road, Rockville, Maryland 20847

https://doi.org/10.1017/S0899823X0008346X Published online by Cambridge University Press